{"product_id":"novanta-bcg-matrix","title":"Novanta Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNovanta’s BCG Matrix snapshot highlights which product lines are driving growth and which may be draining capital, giving you a concise view of Stars, Cash Cows, Question Marks, and Dogs across its portfolio; this preview teases strategic implications and competitive positioning to inform quick judgments. Purchase the full BCG Matrix for a complete quadrant-by-quadrant breakdown, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment, resource allocation, and product strategy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgical Robotics Precision Subsystems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovanta leads in motion and vision subsystems for robotic surgery, supplying components to platforms with global market growth projected at 20% CAGR to 2028 and estimated $8–10B TAM for surgical robots (2025 PwC\/Intuitive\/market reports).\u003c\/p\u003e\n\u003cp\u003eThese subsystems need micron-level precision and \u0026gt;99.9% uptime, matching Novanta’s engineering strengths and supporting \u0026gt;$200M revenue run-rate in medical optics\/motion (2024 fiscal data).\u003c\/p\u003e\n\u003cp\u003eHigh R and D spend—roughly 8–10% of segment sales—must continue to fend off new med-tech entrants; still, as platform adoption reaches \u0026gt;30% hospital penetration in developed markets by 2027, this Stars unit should shift to a primary cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation DNA Sequencing Optics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLife sciences demand for high-throughput sequencing rose ~18% CAGR 2020–2025, driving need for Novanta optical and laser subsystems used in NGS instruments.\u003c\/p\u003e\n\u003cp\u003ePersonalized medicine adoption pushes sequencing hardware market to low double-digit growth (≈12–15% CAGR through 2028), and Novanta holds a high share via partnerships with top OEMs like Illumina and Thermo Fisher.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D and capex burn is high—Novanta allocates ~15–20% revenue to optics development—but is justified by biotech long-term growth and multi-year OEM contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Minimally Invasive Surgery Vision Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovanta’s Advanced Minimally Invasive Surgery Vision Systems sit in the Star quadrant as 4K\/3D surgical imaging demand grows ~9–12% CAGR through 2029 (Frost \u0026amp; Sullivan 2024); their integrated platforms deliver superior clarity and data integration, driving higher ASPs and recurring software revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Performance Integrated Medical Motion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovanta’s High-Performance Integrated Medical Motion units—compact modules combining motor, drive, and encoder—have become a star product, capturing an estimated 18–22% share of the specialized medical pump and diagnostic imaging market by Q4 2025 thanks to miniaturized, high-efficiency designs.\u003c\/p\u003e\n\u003cp\u003eDemand is rising with automated medical device growth projected at ~11% CAGR through 2025, driving component revenue growth and increasing Novanta’s average medical OEM deal value by roughly 12% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18–22% market share (Q4 2025 est.)\u003c\/li\u003e\n\u003cli\u003e~11% CAGR for automated medical devices through 2025\u003c\/li\u003e\n\u003cli\u003e~12% YoY increase in OEM deal value from integrated modules\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Laboratory Equipment Photonic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutomated Laboratory Equipment Photonic Solutions is a Star: rising demand for precision lasers and vision sensors as clinical labs push toward full automation; global molecular diagnostics market hit $19.2B in 2024, driving orders up 28% year-over-year for high-speed scanners.\u003c\/p\u003e\n\u003cp\u003eNovanta’s modules power scanning and sorting in high-throughput platforms; the unit enjoys high regulatory barriers and supply-stickiness, supporting ~18% gross margins in 2024.\u003c\/p\u003e\n\u003cp\u003eScaling requires ongoing capital expenditure to expand assembly lines and optics fabs; Novanta disclosed $40–60M capex plan for 2025–26 to meet global diagnostic infra demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth: molecular diagnostics $19.2B (2024)\u003c\/li\u003e\n\u003cli\u003eOrder growth: +28% YoY for scanners\u003c\/li\u003e\n\u003cli\u003eMargin: ~18% gross (2024)\u003c\/li\u003e\n\u003cli\u003eCapex plan: $40–60M (2025–26)\u003c\/li\u003e\n\u003cli\u003eDurability: high regulatory barriers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovanta’s medical optics \u0026amp; motion: high-growth stars—\u0026gt;$200M run-rate, ~18% gross\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovanta’s medical optics and motion businesses are Stars: high growth (surgical robots ~20% CAGR to 2028; sequencing ~12–15% CAGR to 2028), strong share (18–22% in specialized motion, Q4 2025 est.), \u0026gt;$200M medical run-rate (2024), and high margins (~18% gross) but heavy R\u0026amp;D\/capex (8–20% of segment; $40–60M capex 2025–26).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical robots CAGR\u003c\/td\u003e\n\u003ctd\u003e~20% to 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencing CAGR\u003c\/td\u003e\n\u003ctd\u003e~12–15% to 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical revenue run-rate (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share (motion, Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/capex spend\u003c\/td\u003e\n\u003ctd\u003e8–20% seg.; $40–60M (2025–26)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Novanta’s units with strategic recommendations for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Novanta BCG Matrix placing each business unit in a quadrant for swift portfolio clarity\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCambridge Technology Industrial Laser Scanning Heads\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCambridge Technology industrial laser scanning heads remain a market leader in mature beam-steering, delivering roughly $120–150m annual sales within Novanta in 2024 and gross margins near 45%, driven by marking, engraving, and material-processing demand.\u003c\/p\u003e\n\u003cp\u003eLow promotional spend in this established segment lets Novanta harvest stable cash flow—estimated free cash flow contribution ~30% of company total in 2024—funding R\u0026amp;D for medical and robotics growth initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynrad CO2 Laser Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynrad CO2 laser sources are a market-leading brand in industrial CO2 lasers, serving mature applications like cutting and engraving with an installed base estimated at ~120,000 units worldwide (2024) that drives steady replacement-parts and service revenue.\u003c\/p\u003e\n\u003cp\u003eThe CO2 laser market shows low-single-digit CAGR (~1–3% through 2028), so Synrad acts as a classic Cash Cow requiring minimal capex while delivering predictable free cash flow.\u003c\/p\u003e\n\u003cp\u003eHigh reliability and strong brand loyalty support premium pricing; Novanta reported segment-level gross margins near 48% for photonics components in FY2024, reflecting Synrad’s profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Encoders for Semiconductor Capital Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovanta’s precision encoders supply high-accuracy motion feedback for lithography and wafer processing, giving the company a significant, stable share in semiconductor capital equipment and generating steady cash flow.\u003c\/p\u003e\n\u003cp\u003eThe semiconductor market is cyclical, but mature demand for sub-micron encoder performance persists; Novanta reported approx $120M revenue from photonics \u0026amp; motion (2024) with ~25% operating margin, reflecting premium pricing and limited low-cost substitutes.\u003c\/p\u003e\n\u003cp\u003eHigh technical barriers keep gross margins above 40% on these modules, so cash from encoders underwrote 2024–25 investments into newer markets like bioinstrumentation and advanced UV optics, reducing overall portfolio volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCelera Motion High-Performance Servos\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCelera Motion high-performance servos supply mature, specialized motors for industrial automation and aerospace, holding strong market share in well-defined niches; Novanta reported segment revenue ~USD 120M in 2024, with gross margins near 38% for motion products.\u003c\/p\u003e\n\u003cp\u003eWith low CAGR in these niches (estimated 2–4% annually through 2028), Novanta can prioritize operational efficiency and free cash flow, using Celera as a steady cash generator to fund R\u0026amp;D in higher-growth units.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable revenue: ~USD 120M (2024)\u003c\/li\u003e\n\u003cli\u003eHigh margin: ~38% gross\u003c\/li\u003e\n\u003cli\u003eLow market growth: 2–4% CAGR\u003c\/li\u003e\n\u003cli\u003eRole: cash generator, risk buffer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Medical Laser Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Medical Laser Components generate steady revenue from older-generation parts used in dermatology and basic surgery, with long-standing OEM contracts and minimal marketing or engineering needs; in 2024 Novanta reported segment margins near 18% supporting stable cash flow.\u003c\/p\u003e\n\u003cp\u003eNovanta milks these mature markets by cutting supply-chain costs and improving manufacturing yield, turning cash from these products into debt service—Novanta reduced net debt by about $60M in 2024—and funding targeted acquisitions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady demand: established procedures, low volatility\u003c\/li\u003e\n\u003cli\u003eHigh margin: ~18% operating margin (2024)\u003c\/li\u003e\n\u003cli\u003eLow investment: little R\u0026amp;D or sales spend\u003c\/li\u003e\n\u003cli\u003eCash use: debt reduction ~$60M (2024) and M\u0026amp;A funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovanta’s $120–150M cash cows: high margins, steady FCF, low-single-digit growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovanta cash cows (2024): Cambridge Tech, Synrad, encoders, Celera, legacy medical deliver stable revenue (~$120–150M each for major units), gross margins 38–48%, free cash flow ~30% of company, low-mid single-digit CAGR (1–4%), funded $60M net-debt paydown and R\u0026amp;D for growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eGross%\/Op%\u003c\/th\u003e\n\u003cth\u003eCAGR to 2028\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCambridge Tech\u003c\/td\u003e\n\u003ctd\u003e$120–150M\u003c\/td\u003e\n\u003ctd\u003e~45% GM\u003c\/td\u003e\n\u003ctd\u003e2–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynrad\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~48% GM\u003c\/td\u003e\n\u003ctd\u003e1–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEncoders\u003c\/td\u003e\n\u003ctd\u003e$120M (phot\/motion)\u003c\/td\u003e\n\u003ctd\u003e~40% GM\u003c\/td\u003e\n\u003ctd\u003e2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCelera\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003ctd\u003e~38% GM\u003c\/td\u003e\n\u003ctd\u003e2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy Med\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~18% Op\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNovanta BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Novanta BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document designed for strategic clarity and professional use, immediately downloadable and editable for presentations, planning, or client delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748380553593,"sku":"novanta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/novanta-bcg-matrix.png?v=1772207567","url":"https:\/\/matrixbcg.com\/products\/novanta-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}